unproven. In that regard, the more recent use of MSCs and related umbilical cord stem cells in largely non-inflammatory and structural conditions such as cerebral palsy (Englander et al., 2015), and in the genetic non-metabolic disorders of myelin such as Pelizaeus-Merzbacher disease (Wishnew et al., 2014), while difficult to logicize or indeed even justify, again reinforces the point that cell therapeutics should being deployed only for those conditions in which their proposed mechanism of action is both well-founded and target-appropriate.
